The Impact of Polypharmacy on Blood Pressure Achievement in Hypertensive Patients with Complications: Pengaruh Polifarmasi terhadap Pencapaian Tekanan Darah pada Pasien Hipertensi dengan Komplikasi

Elly Megasari; Syarofina Diniati; Arifani Siswidiasari; Tsamrotul Ilmi; Henni wati

doi:10.53342/pharmasci.v11i2.599

Authors

Elly Megasari Universitas Kadiri
Syarofina Diniati
Arifani Siswidiasari
Tsamrotul Ilmi
Henni wati

DOI:

https://doi.org/10.53342/pharmasci.v11i2.599

Keywords:

Hipertensi,, Polifarmasi,, Antihipertensi,, Target tekanan darah,, Spearman Rank,

Abstract

Hypertension is a non-communicable disease and a major risk factor for cardiovascular disease. Polypharmacy, defined as the concurrent use of multiple medications, is commonly observed in hypertensive patients, particularly those with comorbidities. Although polypharmacy may improve therapeutic outcomes, it also increases the risk of drug interactions, adverse drug reactions, and poor medication adherence, which may affect blood pressure control. This study aimed to describe the pattern of polypharmacy and evaluate its association with blood pressure target achievement among hypertensive patients. An analytical observational study with a cross-sectional design was conducted using retrospective data collected from the medical records of 75 eligible hypertensive patients. The association between polypharmacy and blood pressure target achievement was analyzed using Spearman's Rank correlation test with a 95% confidence level. The results showed that the most frequently prescribed antihypertensive regimen was a two-drug combination (25%), while the most commonly used antihypertensive class was the Angiotensin Receptor Blocker (ARB), particularly candesartan. Most patients experienced mild polypharmacy (<5 medications) (64%), followed by severe polypharmacy (>5 medications) (21.3%), whereas 14.7% did not experience polypharmacy. Only 36% of patients achieved the target blood pressure, while 64% failed to reach the target. Spearman's Rank analysis demonstrated no significant association between polypharmacy and blood pressure target achievement (p = 0.135; r = -0.174). Although no significant relationship was identified, regular evaluation of polypharmacy remains essential to minimize drug interactions and optimize therapeutic outcomes in hypertensive patients.

References

1. McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, Christodorescu RM, et al. 2021 World Health Organization guideline on pharmacological treatment of hypertension: Policy implications for the Region of the Americas. Rev Panam Salud Publica/Pan Am J Public Heal [Internet]. 2024;45(38):3912–4018. Available from: https://doi.org/10.1016/j.lana.2022.100219

2. WHO. Hypertension Indonesia Tahun 2023. 2023;(2019):1. Available from: https://www.who.int/publications/m/item/hypertension-idn-2023-country-profile

3. Oliveros E, Patel H, Kyung S, Fugar S, Goldberg A, Madan N, et al. Hypertension in older adults: Assessment, management, and challenges. Vol. 43, Clinical Cardiology. 2020. p. 99–107.

4. Campbell NRC, Burnens MP, Whelton PK, Angell SY, Jaffe MG, Cohn J, et al. 2021 World Health Organization guideline on pharmacological treatment of hypertension: Policy implications for the Region of the Americas. Rev Panam Salud Publica/Pan Am J Public Heal [Internet]. 2022;46:100219. Available from: https://doi.org/10.1016/j.lana.2022.100219

5. Indonesia KKR. Profil Kesehatan Profil Kesehatan. Buku. 2024. 14 p.

6. Kemenkes. Survei Kesehatan Indonesia (SKI) 2023. Kemenkes. 2023;235.

7. Bonanno EG, Figueiredo T, Mimoso IF, Morgado MI, Carrilho J, Midão L, et al. Polypharmacy Prevalence Among Older Adults Based on the Survey of Health, Ageing and Retirement in Europe: An Update. J Clin Med. 2025;14(4).

8. Lampe D, Grosser J, Gensorowsky D, Witte J, Muth C, van den Akker M, et al. The Relationship of Continuity of Care, Polypharmacy and Medication Appropriateness: A Systematic Review of Observational Studies. Drugs and Aging [Internet]. 2023;40(6):473–97. Available from: https://doi.org/10.1007/s40266-023-01022-8

9. Sangaleti CT, Lentsck MH, da Silva DC, Machado A, Trincaus MR, Vieira MCU, et al. Polypharmacy, potentially inappropriate medications and associated factors among older adults with hypertension in primary care. Rev Bras Enferm. 2023;76(Suppl 2):8–14.

10. Kusumawardani LA, Andrajati R, Nusaibah A. Drug-related Problems in Hypertensive Patients: A Cross-sectional Study from Indonesia. J Res Pharm Pract. 2020;9(3):140–5.

11. Wijaya IN, Athiyah U, Fasich, Rahem A, Hermansyah A. The association between drug therapy problems and blood pressure control of patients with hypertension in public health center setting. J Public Health Africa. 2023;14(S1):137–40.

12. Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019) [Internet]. Vol. 42, Hypertension Research. Springer US; 2019. p. 1235–481. Available from: http://dx.doi.org/10.1038/s41440-019-0284-9

13. PCNE. Pharmaceutical Care Network Europe v9.00 - Bahasa Indonesia. Pharm Care Netw Eur. 2023;9–10.

14. Barbara GW, Joseph TD, Cecily VD, L. ST. Pharmacoterapy A Phatophysiologic Approach. United State: McGraw-Hill Education. 2015. 1–4485 p.

15. PERKI. Panduan Promotif dan Preventif Hipertensi 2023. Indones Soc Hypertens Perhimpun Dr Hipertens Indones [Internet]. 2023;50–1.Availablefrom:http://www.inash.or.id/upload/event/event_Update_konsensus_2019123191.pdf

16. Lee JW, Gu HO, Jung Y, Jung YJ, Seo SY, Hong JH, et al. Candesartan, an angiotensin-II receptor blocker, ameliorates insulin resistance and hepatosteatosis by reducing intracellular calcium overload and lipid accumulation. Exp Mol Med. 2023;55(5):910–25.

17. Ridwan BA, Rachmah IM. Hubungan Kejadian Drug Related Problems (DRPs) dengan Ketercapaian Target Tekanan Darah Pasien Hipertensi di Puskesmas Lalonggasumeeto Kabupaten Konawe. J Farm DAN Kesehat Indones. 2023;3(2):103–13.

18. Wulansari A, Rosady A, Adelia DA. Pola Penggunaan Obat Antihipertensi Pasien Hipertensi Poliklinik rawat jalan RSWK Purwokerto Oktober- Desember 2022. J Pharmacopolium. 2023;6(3):69–75.

19. Oktadiana I, Asrita Pinem M, Sugesti E, Siregar A. Evaluasi Rasionalitas Penggunaan Obat Pada Pasien Hipertensi Rawat Jalan Di RSUD Perdagangan Tahun 2024. Duta Pharma J. 2024;4(2):332–7.

20. Kumalasari A, Endrawati S, Wahyuningsih SS, Indrasari T. Hubungan Polifarmasi dan Potensi Interaksi Obat Antihipertensi Pada Pasien Rawat Jalan di RSUD dr. Soehadi Prijonegoro Sragen. Indones J Med Sci. 2025;12(1).

21. WHO. Hypertension Indonesia Tahun 2023. 2023;(2019):1. Available from: https://www.who.int/publications/m/item/hypertension-idn-2023-country-profileb

22. Padoma C, Mongi J, Tampa’I R, Kanter JW, Rumagit H, Potalangi NO. Evaluasi Kerasionalan Penggunaan Antihipertensi Pada Pasien Hipertensi Rawat Jalan Di RSUD Maria Walanda Maramis. Biofarmasetikal Trop (The Trop J Biopharm. 2023;6(2):9–12.